Literature DB >> 25154780

Identification and characterisation of peptide binding motifs of six autoimmune disease-associated human leukocyte antigen-class I molecules including HLA-B*39:06.

M Eichmann1, A de Ru, P A van Veelen, M Peakman, D Kronenberg-Versteeg.   

Abstract

Research on CD8 T cell-mediated inflammatory diseases requires a better understanding of target epitopes and the constraints placed upon these by major histocompatibility complex (MHC) class I binding restrictions, especially those that relate to predisposing alleles. We used linear trap quadrupole fourier transform (LTQ-FT) tandem mass spectrometry to identify naturally processed and presented peptides eluted from the MHC-negative myeloid leukaemia cell line K562 transfected with specific MHC class I genes. We provide information on the peptidome of HLA-B*39:06, which is associated with the autoimmune disease type 1 diabetes, and extend the analysis to include a further five human leukocyte antigen (HLA) alleles (HLA-A*02:01/-A*11:01/-A*24:02/-B*18:01/-B*38:01) studied under identical experimental conditions. We identified a total of 3095 individual peptides with a mascot score ≥40 (HLA-A*02:01 = 569 peptides, -A*11:01 = 904, A*24:02 = 257, -B*18:01 = 615, -B*38:01 = 453, -B*39:06 = 297). Peptides had a preferential length of nine amino acids and originated mainly from cytoplasmic or nuclear proteins. Eluted peptides revealed a strong binding motif with binding anchor positions at position 2 (P2) and the C-terminus (PΩ). Peptides eluted from HLA-A*02:01 showed a P2 preference for leucine (62% of total peptides have Leu at P2) and PΩ preference for valine (49%). Similar data are provided for HLA-A*11:01 (P2:Thr, 29%; PΩ:Lys, 49%), -A*24:02 (P2:Tyr, 78%; PΩ:Phe, 41%), -B*18:01 (P2:Glu, 77%; PΩ:Tyr, 32%), -B*38:01 (P2:His, 51%; PΩ:Leu, 45%) and -B*39:06 (P2:Arg/His, 24%; PΩ:Ala, 64%). This work thus gives an overview of the naturally processed and presented repertoire of several common and autoimmune disease-related HLA alleles, which may be useful in studying autoreactive CD8 T cell responses and the role of HLA in disease susceptibility.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  antigen presentation; binding motif; immunopeptidome; mass spectrometry

Mesh:

Substances:

Year:  2014        PMID: 25154780     DOI: 10.1111/tan.12413

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  12 in total

1.  Mass Spectrometry Profiling of HLA-Associated Peptidomes in Mono-allelic Cells Enables More Accurate Epitope Prediction.

Authors:  Jennifer G Abelin; Derin B Keskin; Siranush Sarkizova; Christina R Hartigan; Wandi Zhang; John Sidney; Jonathan Stevens; William Lane; Guang Lan Zhang; Thomas M Eisenhaure; Karl R Clauser; Nir Hacohen; Michael S Rooney; Steven A Carr; Catherine J Wu
Journal:  Immunity       Date:  2017-02-21       Impact factor: 31.745

2.  HLA-B*39:06 Efficiently Mediates Type 1 Diabetes in a Mouse Model Incorporating Reduced Thymic Insulin Expression.

Authors:  Jennifer Schloss; Riyasat Ali; Jeremy J Racine; Harold D Chapman; David V Serreze; Teresa P DiLorenzo
Journal:  J Immunol       Date:  2018-04-09       Impact factor: 5.422

3.  Characterization of the peptide binding specificity of the HLA class I alleles B*38:01 and B*39:06.

Authors:  John Sidney; Jennifer Schloss; Carrie Moore; Mikaela Lindvall; Amanda Wriston; Donald F Hunt; Jeffrey Shabanowitz; Teresa P DiLorenzo; Alessandro Sette
Journal:  Immunogenetics       Date:  2016-01-11       Impact factor: 3.330

4.  Database search engines and target database features impinge upon the identification of post-translationally cis-spliced peptides in HLA class I immunopeptidomes.

Authors:  Michele Mishto; Yehor Horokhovskyi; John A Cormican; Xiaoping Yang; Steven Lynham; Henning Urlaub; Juliane Liepe
Journal:  Proteomics       Date:  2022-03-03       Impact factor: 5.393

5.  Neoantigen characteristics in the context of the complete predicted MHC class I self-immunopeptidome.

Authors:  Scott D Brown; Robert A Holt
Journal:  Oncoimmunology       Date:  2018-12-22       Impact factor: 8.110

6.  Keratin 8 is a potential self-antigen in the coronary artery disease immunopeptidome: A translational approach.

Authors:  Peter M Mihailovic; Wai Man Lio; Romana Herscovici; Kuang-Yuh Chyu; Juliana Yano; Xiaoning Zhao; Jianchang Zhou; Bo Zhou; Michael R Freeman; Wei Yang; Prediman K Shah; Bojan Cercek; Paul C Dimayuga
Journal:  PLoS One       Date:  2019-02-27       Impact factor: 3.240

7.  NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets.

Authors:  Morten Nielsen; Massimo Andreatta
Journal:  Genome Med       Date:  2016-03-30       Impact factor: 11.117

8.  Systematic identification of cancer-specific MHC-binding peptides with RAVEN.

Authors:  Michaela C Baldauf; Julia S Gerke; Andreas Kirschner; Franziska Blaeschke; Manuel Effenberger; Kilian Schober; Rebeca Alba Rubio; Takayuki Kanaseki; Merve M Kiran; Marlene Dallmayer; Julian Musa; Nurset Akpolat; Ayse N Akatli; Fernando C Rosman; Özlem Özen; Shintaro Sugita; Tadashi Hasegawa; Haruhiko Sugimura; Daniel Baumhoer; Maximilian M L Knott; Giuseppina Sannino; Aruna Marchetto; Jing Li; Dirk H Busch; Tobias Feuchtinger; Shunya Ohmura; Martin F Orth; Uwe Thiel; Thomas Kirchner; Thomas G P Grünewald
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

9.  An effective CTL peptide vaccine for Ebola Zaire Based on Survivors' CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design.

Authors:  C V Herst; S Burkholz; J Sidney; A Sette; P E Harris; S Massey; T Brasel; E Cunha-Neto; D S Rosa; W C H Chao; R Carback; T Hodge; L Wang; S Ciotlos; P Lloyd; R Rubsamen
Journal:  Vaccine       Date:  2020-04-28       Impact factor: 3.641

10.  Circulating β cell-specific CD8+ T cells restricted by high-risk HLA class I molecules show antigen experience in children with and at risk of type 1 diabetes.

Authors:  L Yeo; I Pujol-Autonell; R Baptista; M Eichmann; D Kronenberg-Versteeg; S Heck; G Dolton; A K Sewell; T Härkönen; M-L Mikk; J Toppari; R Veijola; M Knip; J Ilonen; M Peakman
Journal:  Clin Exp Immunol       Date:  2019-11-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.